|
1
|
Mirabello L, Troisi RJ and Savage SA:
Osteosarcoma incidence and survival rates from 1973 to 2004: Data
from the surveillance, epidemiology and end results program.
Cancer. 115:1531–1543. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bielack S, Carrle D and Casali PG: ESMO
Guidelines Working Group: Osteosarcoma: ESMO clinical
recommendations for diagnosis, treatment and follow-up. Ann Oncol.
20 Suppl 4:S137–S139. 2009. View Article : Google Scholar
|
|
3
|
Bielack SS, Kempf-Bielack B, Delling G,
Exner GU, Flege S, Helmke K, Kotz R, Salzer-Kuntschik M, Werner M,
Winkelmann W, et al: Prognostic factors in high-grade osteosarcoma
of the extremities or trunk: An analysis of 1,702 patients treated
on neoadjuvant cooperative osteosarcoma study group protocols. J
Clin Oncol. 20:776–790. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Marina N, Gebhardt M, Teot L and Gorlick
R: Biology and therapeutic advances for pediatric osteosarcoma.
Oncologist. 9:422–441. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kansara M, Teng MW, Smyth MJ and Thomas
DM: Translational biology of osteosarcoma. Nat Rev Cancer.
14:722–735. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Nieman MT, Prudoff RS, Johnson KR and
Wheelock MJ: N-cadherin promotes motility in human breast cancer
cells regardless of their E-cadherin expression. J Cell Biol.
147:631–644. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Islam S, Carey TE, Wolf GT, Wheelock MJ
and Johnson KR: Expression of N-cadherin by human squamous
carcinoma cells induces a scattered fibroblastic phenotype with
disrupted cell-cell adhesion. J Cell Biol. 135:1643–1654. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Nishitani S, Noma K, Ohara T, Tomono Y,
Watanabe S, Tazawa H, Shirakawa Y and Fujiwara T: Iron
depletion-induced downregulation of N-cadherin expression inhibits
invasive malignant phenotypes in human esophageal cancer. Int J
Oncol. 49:1351–1359. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Park KS, Dubon MJ and Gumbiner BM:
N-cadherin mediates the migration of MCF-10A cells undergoing bone
morphogenetic protein 4-mediated epithelial mesenchymal transition.
Tumour Biol. 36:3549–3556. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bremmer F, Schallenberg S, Jarry H, Küffer
S, Kaulfuss S, Burfeind P, Strauß A, Thelen P, Radzun HJ, Ströbel
P, et al: Role of N-cadherin in proliferation, migration, and
invasion of germ cell tumours. Oncotarget. 6:33426–33437. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Da C, Wu K, Yue C, Bai P, Wang R, Wang G,
Zhao M, Lv Y and Hou P: N-cadherin promotes thyroid tumorigenesis
through modulating major signaling pathways. Oncotarget.
8:8131–8142. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Michishita E, McCord RA, Berber E, Kioi M,
Padilla-Nash H, Damian M, Cheung P, Kusumoto R, Kawahara TL,
Barrett JC, et al: SIRT6 is a histone H3 lysine 9 deacetylase that
modulates telomeric chromatin. Nature. 452:492–496. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sebastián C, Zwaans BM, Silberman DM,
Gymrek M, Goren A, Zhong L, Ram O, Truelove J, Guimaraes AR, Toiber
D, et al: The histone deacetylase SIRT6 is a tumor suppressor that
controls cancer metabolism. Cell. 151:1185–1199. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tian K, Chen P, Liu Z, Si S, Zhang Q, Mou
Y, Han L, Wang Q and Zhou X: Sirtuin 6 inhibits epithelial to
mesenchymal transition during idiopathic pulmonary fibrosis via
inactivating TGF-β1/Smad3 signaling. Oncotarget. 8:61011–61024.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bai L, Lin G, Sun L, Liu Y, Huang X, Cao
C, Guo Y and Xie C: Upregulation of SIRT6 predicts poor prognosis
and promotes metastasis of non-small cell lung cancer via the
ERK1/2/MMP9 pathway. Oncotarget. 7:40377–40386. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kugel S, Sebastián C, Fitamant J, Ross KN,
Saha SK, Jain E, Gladden A, Arora KS, Kato Y, Rivera MN, et al:
SIRT6 suppresses pancreatic cancer through control of Lin28b. Cell.
165:1401–1415. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Elhanati S, Ben-Hamo R, Kanfi Y, Varvak A,
Glazz R, Lerrer B, Efroni S and Cohen HY: Reciprocal regulation
between SIRT6 and miR-122 controls liver metabolism and predicts
hepatocarcinoma prognosis. Cell Rep. 14:234–242. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Liszt G, Ford E, Kurtev M and Guarente L:
Mouse Sir2 homolog SIRT6 is a nuclear ADP-ribosyltransferase. J
Biol Chem. 280:21313–21320. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Mostoslavsky R, Chua KF, Lombard DB, Pang
WW, Fischer MR, Gellon L, Liu P, Mostoslavsky G, Franco S, Murphy
MM, et al: Genomic instability and aging-like phenotype in the
absence of mammalian SIRT6. Cell. 124:315–329. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhang P, Tu B, Wang H, Cao Z, Tang M,
Zhang C, Gu B, Li Z, Wang L, Yang Y, et al: Tumor suppressor p53
cooperates with SIRT6 to regulate gluconeogenesis by promoting
FoxO1 nuclear exclusion. Proc Natl Acad Sci USA. 111:10684–10689.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Marquardt JU, Fischer K, Baus K, Kashyap
A, Ma S, Krupp M, Linke M, Teufel A, Zechner U, Strand D, et al:
Sirtuin-6-dependent genetic and epigenetic alterations are
associated with poor clinical outcome in hepatocellular carcinoma
patients. Hepatology. 58:1054–1064. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Feng J, Yan PF, Zhao HY, Zhang FC, Zhao WH
and Feng M: SIRT6 suppresses glioma cell growth via induction of
apoptosis, inhibition of oxidative stress and suppression of
JAK2/STAT3 signaling pathway activation. Oncol Rep. 35:1395–1402.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kok SH, Hou KL, Hong CY, Chao LH,
Hsiang-Hua Lai E, Wang HW, Yang H, Shun CT, Wang JS and Lin SK:
Sirtuin 6 modulates hypoxia-induced apoptosis in osteoblasts via
inhibition of glycolysis: Implication for pathogenesis of
periapical lesions. J Endod. 41:1631–1637. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sugatani T, Agapova O, Malluche HH and
Hruska KA: SIRT6 deficiency culminates in low-turnover osteopenia.
Bone. 81:168–177. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhang DM, Cui DX, Xu RS, Zhou YC, Zheng
LW, Liu P and Zhou XD: Phenotypic research on senile osteoporosis
caused by SIRT6 deficiency. Int J Oral Sci. 8:84–92. 2016.
View Article : Google Scholar : PubMed/NCBI
|
